- Atomoxetine (Strattera®)
- Citalopram (Celexa®)
- Coenzyme Q-10 - PREQUEL
- Creatine - PRECREST
- Ethyl-EPA (Miraxion)
- Memantine (Namenda®)
- Minocycline (Minocin®)
- Tetrabenazine (Nitoman®, Xenazine®)
Clinical Trial Background by Huntington Study Group (HSG)
Clinical Trial Background by NIH ClinicalTrials.gov
List of Clinical Trials by NIH ClinicalTrials.gov
Trial information at NIH ClincalTrials.gov
Trial status: Completed.
Trial name: CIT-HD
FDA phase: Phase II
Trial results: Citalopram did not significantly improve executive cognitive function in 20 study participants.
Trial design: A randomized, double-blind, placebo-controlled, pilot clinical trial in 20 people with HD between the ages of 18 and 60, to consider the efficacy of citalopram. The trial lasts about 21 weeks and requires eight outpatient visits and two telephone visits. Participants will be offered travel reimbursement and some compensation for participation.
Outcome measures: Comparison of executive function before and after treatment. Other assessments include cognitive and functional measures and brain imaging.
Location: University of Iowa